Conformis (NASDAQ:CFMS) Receives New Coverage from Analysts at StockNews.com

Equities researchers at StockNews.com began coverage on shares of Conformis (NASDAQ:CFMS – Get Rating) in a report issued on Friday. The brokerage set a “hold” rating on the medical instruments supplier’s stock.

Separately, Oppenheimer lowered Conformis from an “outperform” rating to a “market perform” rating in a research report on Tuesday, May 9th.

Conformis Trading Down 8.9 %

Shares of CFMS stock opened at $1.23 on Friday. Conformis has a 12-month low of $1.05 and a 12-month high of $11.25. The company has a current ratio of 5.71, a quick ratio of 4.06 and a debt-to-equity ratio of 0.46. The stock’s 50-day moving average price is $1.46 and its 200-day moving average price is $2.20. The stock has a market capitalization of $9.23 million, a price-to-earnings ratio of -0.20 and a beta of 1.09.

Conformis (NASDAQ:CFMS – Get Rating) last issued its earnings results on Wednesday, March 1st. The medical instruments supplier reported ($0.51) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.84) by $1.33. The firm had revenue of $17.42 million for the quarter, compared to analysts’ expectations of $13.84 million. Conformis had a negative return on equity of 75.43% and a negative net margin of 74.18%. Equities research analysts predict that Conformis will post -5.2 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the business. UBS Group AG boosted its position in shares of Conformis by 24.7% during the first quarter. UBS Group AG now owns 115,831 shares of the medical instruments supplier’s stock valued at $186,000 after buying an additional 22,911 shares during the period. Dimensional Fund Advisors LP purchased a new position in shares of Conformis during the fourth quarter valued at approximately $91,000. Bank of New York Mellon Corp boosted its position in shares of Conformis by 2.3% during the third quarter. Bank of New York Mellon Corp now owns 368,020 shares of the medical instruments supplier’s stock valued at $71,000 after buying an additional 8,191 shares during the period. Renaissance Technologies LLC boosted its position in shares of Conformis by 4.1% during the third quarter. Renaissance Technologies LLC now owns 4,763,691 shares of the medical instruments supplier’s stock valued at $911,000 after buying an additional 188,200 shares during the period. Finally, MYDA Advisors LLC purchased a new position in shares of Conformis during the third quarter valued at approximately $133,000.

Conformis Company Profile

(Get Rating)

ConforMIS, Inc is a medical technology company, which engages in the development, manufacture, and sale of joint replacement implants. It operates through the following geographical segments: United States, Germany, and Rest of the World. The firm’s products include iUni, iDuo, iTotal CR, and iTotal.